Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer - Drug Trials For Money - Paid Clinical Trials

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube High Grade Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian High Grade Serous Adenocarcinoma;   Primary Peritoneal Endometrioid Adenocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Unresectable Fallopian Tube Endometrioid Adenocarcinoma;   Unresectable Fallopian Tube High Grade Serous Adenocarcinoma;   Unresectable Ovarian Endometrioid Adenocarcinoma;   Unresectable Ovarian High Grade Serous Adenocarcinoma;   Unresectable Primary Peritoneal Endometrioid Adenocarcinoma;   Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions:   Procedure: Biopsy;   Drug: Carboplatin;   Drug: Ipatasertib;   Drug: Paclitaxel
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 8, 2022 / by / in
Comments